Novonesis Posts 7% Organic Sales Growth in Q1 2026 Amid Global Uncertainty
Event summary
- Novonesis reported 7% organic sales growth in Q1 2026, with adjusted EBITDA margin at 37.8%.
- Food & Health Biosolutions grew 9% organically, while Planetary Health Biosolutions grew 5%.
- Developed Markets saw 8% organic growth, Emerging Markets grew 4% (including ~3 pp effect from exiting certain countries).
- Company completed EUR 1.7 billion bond issuance to refinance a bridge loan facility.
- 2026 outlook confirmed: 5-7% organic sales growth expected, with adjusted EBITDA margin between 37-38%.
The big picture
Novonesis's strong Q1 2026 performance underscores the growing demand for biosolutions in both developed and emerging markets. The company's ability to maintain high EBITDA margins despite currency headwinds highlights its operational resilience. The EUR 1.7 billion bond issuance reflects strategic financial maneuvering to support long-term growth initiatives, particularly in expanding its production capabilities.
What we're watching
- Market Resilience
- How Novonesis will sustain growth amid global uncertainty and currency headwinds.
- Execution Risk
- Whether the company can meet its 2030 targets, including a 6–9% organic sales growth CAGR.
- Strategic Expansion
- The pace at which Novonesis integrates its new production facility in Thailand.
Related topics